Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies

American Journal of Psychiatry

Volumn 170, Issue 2, 2013, Pages 207-217

  Uher, Rudolf ^a,b   Tansey, Katherine E ^a   Rietschel, Marcella ^c   Henigsberg, Neven ^d   Maier, Wolfgang ^c   Mors, Ole ^e   Hauser, Joanna ^f   Placentino, Anna ^g   Souery, Daniel ^h   Farmer, Anne ^a   Aitchison, Katherine J ^a,i   Craig, Ian ^a   McGuffin, Peter ^a   Lewis, Cathryn M ^a   Ising, Marcus ^j   Lucae, Susanne ^j   Binder, Elisabeth B ^j   Kloiber, Stefan ^j   Holsboer, Florian ^j   Müller Myhsok, Bertram ^j   Ripke, Stephan ^k   Hamilton, Steven P ^l   Soundy, Jared ^m   Laje, Gonzalo ⁿ   McMahon, Francis J ⁿ   Fava, Maurizio ^k   Rush, A John ^o   Perlis, Roy H ^k   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b DALHOUSIE UNIVERSITY   (Canada)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^h ERASME HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m AUGUSTANA COLLEGE   (United States)

ⁿ NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^o DUKE NUS MEDICAL SCHOOL   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DNA; ESCITALOPRAM; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CHROMOSOME 5; DRUG EFFICACY; DRUG RESPONSE; EUROPEAN AMERICAN; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MULTICENTER STUDY (TOPIC); NATURALISTIC INQUIRY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

EID: 84873348443     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12020237     Document Type: Article

References (46)

1. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53
2. Fountoulakis KN, Möller HJ: Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuro- psychopharmacol 2011; 14: 405-412
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
4. Angst J: Effect of antidepressives and genetic factors. Arzneimittelforschung 1964; 14(Suppl): 496-500
5. Franchini L, Serretti A, Gasperini M, Smeraldi E: Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 255-259
6. O'Reilly RL, Bogue L, Singh SM: Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994; 36: 467-471
7. Crowley JJ, Blendy JA, Lucki I: Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl) 2005; 183: 257-264
8. Crowley JJ, Brodkin ES, Blendy JA, Berrettini WH, Lucki I: Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 2006; 31: 2433-2442
9. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252
10. Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, Nejjari C, Patsch W, Chikri M, Meyre D, Froguel P: TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med (Berl) 2007; 85: 777-782
11. Roberts R, Wells GA, Stewart AF, Dandona S, Chen L: The genome-wide association study - a new era for common polygenic disorders. J Cardiovasc Transl Res 2010; 3: 173-182
12. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S, Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M, Morris DW, Elkin A, Muir WJ, McGhee KA, Williamson R, MacIntyre DJ, MacLean AW, St CD, Robinson M, Van Beck M, Pereira AC, Kandaswamy R, McQuillin A, Collier DA, Bass NJ, Young AH, Lawrence J, Ferrier IN, Anjorin A, Farmer A, Curtis D, Scolnick EM, McGuffin P, Daly MJ, Corvin AP, Holmans PA, Blackwood DH, Gurling HM, Owen MJ, Purcell SM, Sklar P, Craddock N; Wellcome Trust Case Control Consortium: Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1Cin bipolar disorder. Nat Genet 2008; 40: 1056-1058
13. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P; International Schizophrenia Consortium: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752
14. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P: Differential efficacy of escitalopram and nor-triptyline on dimensional measures of depression. Br J Psychiatry 2009; 194: 252-259
15. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P: Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564
16. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B, Spieler D, Messer T, Lutz R, Künzel H, Bierner T, Pollmächer T, Pfister H, Nickel T, Sonntag A, Uhr M, Ising M, Holsboer F, Lucae S: Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43: 215-229
17. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B: A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966-975
18. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP: A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-138
19. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group: Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119-142
20. Wing JK, Sartorius N, Ustin TB: Diagnosis and Clinical Measurement in Psychiatry: A Reference Manual for SCAN. Geneva, World Health Organization, 1998
21. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, Henigsberg N, Perez J, Mendlewicz J, Janzing JG, Zobel A, Skibinska M, Kozel D, Stamp AS, Bajs M, Placentino A, Barreto M, McGuffin P, Aitchison KJ: Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008; 38: 289-300
22. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
23. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M: An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biol Psychiatry 2006; 59: 493-501
24. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH: Selecting among second-step anti-depressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008; 65: 870-880
25. Sidor MM, Macqueen GM: Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72: 156-167
26. Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP: A comparison of depression rating scales. Br J Psychiatry 1982; 141: 45-49
27. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S: Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1981; 38: 98-103
28. Uher R, Muthén B, Souery D, Mors O, Jaracz J, Placentino A, Petrovic A, Zobel A, Henigsberg N, Rietschel M, Aitchison KJ, Farmer A, McGuffin P: Trajectories of change in depression severity during treatment with antidepressants. Psychol Med 2010; 40: 1367-1377
29. Prien RF, Carpenter LL, Kupfer DJ: The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature. Arch Gen Psychiatry 1991; 48: 796-800
30. Adkins DE, Aberg K, McClay JL, Hettema JM, Kornstein SG, Bukszár J, van den Oord EJ: A genomewide association study of citalopram response in major depressive disorder - a psychometric approach. Biol Psychiatry 2010; 68: e25-e27
31. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-141
32. Deyi BA, Kosinski AS, Snapinn SM: Power considerations when a continuous outcome variable is dichotomized. J Biopharm Stat 1998; 8: 337-352
33. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF: A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 2009; 107: 13-21
34. Browning BL, Browning SR: A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 2009; 84: 210-223
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
36. Willer CJ, Li Y, Abecasis GR: METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010; 26: 2190-2191
37. Dudbridge F, Gusnanto A: Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008; 32: 227-234
38. Lin DY, Zeng D: Meta-analysis of genome-wide association studies: no efficiency gain in using individual participant data. Genet Epidemiol 2010; 34: 60-66
39. Uher R, Tansey KE, Malki K, Perlis RH: Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 2012; 13: 233-240
40. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54: 1609-1616
41. Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-1847
42. Merlo-Pich E, Alexander RC, Fava M, Gomeni R: A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther 2010; 88: 634-642
43. Muthén B, Brown HC: Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med 2009; 28: 3363-3385
44. Perlis RH: Translating biomarkers to clinical practice. Mol Psychiatry 2011; 16: 1076-1087
45. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm 1992; 88: 157-160
46. Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P: Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012; 42: 967-980